27276 results about "Polysaccharide" patented technology

A bicomposite material based on collagen is prepared which has two closely bound layers and is biocompatible, non-toxic, hemostatic and biodegradable in less than a month, and can be used in surgery to achieve hemostasis and prevent post-surgical adhesion. To prepare the material, a solution of collagen or gelatin, which may contain glycerine and a hydrophilic additive such as polyethylene glycol or a polysaccharide, is poured onto an inert support to form a layer 30 .mu.m to less than 100 .mu.m thick. Then a polymeric porous fibrous layer is applied during gelling of the collagen or gelatin, and the resultant material is dried. The polymeric porous fibrous layer may be made of collagen or a polysaccharide, and have a density of not more than 75 mg / cm.sup.2, a pore size from 30 .mu.m to 300 .mu.m and a thickness of 0.2 cm to 1.5 cm.

This invention pertains to novel fibers made of α(1→;3) polysaccharides, and a process for their production. The fibers of the invention have “cotton-like” properties but can be produced as continuous filaments on a year-round basis. The fibers are useful in textile applications.

Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel through an orifice at the target site. Alternatively, the gels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Disclosed and claimed are a method for the purification of polysaccharide-protein conjugate vaccines by ultrafiltration in a saturated solution of ammonium sulfate. The ultrafiltration method of the present invention provides an efficient, readily scalable method for removal of unbound polysaccharides from polysaccharide-protein vaccines, thereby improving the purity and consistency of the polysaccharide-protein vaccines.

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compositions made of inter-macromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and / or polycations. The polymers are associated with each other and are then either dried into membranes or sponges or are used as fluids or microspheres. Bioresorbable, bioadhesive, antiadhesion compositions are useful in surgery to prevent the formation and reformation of post-surgical adhesions. The compositions are designed to breakdown in vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aqueous solutions. The antiadhesion, bioadhesive, bioresorptive, antithrombogenic and physical properties of such membranes and gels can be varied as needed by carefully adjusting the pH and / or cation content of the polymer casting solutions, polyacid composition, the polyalkylene oxide composition, or by conditioning the membranes prior to surgical use. Multi-layered membranes can be made and used to provide further control over the physical and biological properties of antiadhesion membranes. Membranes and gels can be used concurrently. Antiadhesion compositions may also be used to lubricate tissues and / or medical instruments, and / or deliver drugs to the surgical site and release them locally.

The invention relates to a liquid phase chip for joint detection of multiple tumor markers and a preparation method thereof. The liquid phase chip comprises micro-balloons of a coupled antibody (at least two of the followings: AFP, CEA, CA125, CA153, CA19-9, CA242, CA72-4, PSA, HGH, Beta-HCG), corresponding biotin-labeled detection antibodies, streptavidin phycoerythrin and vegetable hydrosol or polysaccharide hydrosol which has a solute content of 1-10 wt per thousand and does not contain protein. The preparation of the liquid phase chip comprises refining and purification of hydrosol, coupling between captured antibodies and micro-balloons, preparation of biotin-labeled antibodies, dispersing the coupled micro-balloons into the vegetable hydrosol or the polysaccharide hydrosol, and the like. The liquid phase chip has the advantages of stable performance, good micro-balloon dispersivity, long preservation time, fast and convenient use and operation, small amount of samples in use, high detection sensitivity, wide linear scope and low detection cost, can detect ten tumor markers at most at one time, and requires a cost which is a quarter of the total fee of conventional methods.

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.

The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and / or polycations. The polymers are associated with each other, and are then either dried into membranes or sponges, or are used as fluids or microspheres. Bioresorbable, bioadhesive, anti-adhesion compositions are useful in surgery to prevent the formation and reformation of post-surgical adhesions. The compositions are designed to breakdown in-vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aqueous solutions. The anti-adhesion, bioadhesive, bioresorptive, antithrombogenic and physical properties of such membranes and gels can be varied as needed by carefully adjusting the pH and / or cation content of the polymer casting solutions, polyacid composition, the polyalkylene oxide composition, or by conditioning the membranes prior to surgical use. Multi-layered membranes can be made and used to provide further control over the physical and biological properties of antiadhesion membranes. Membranes and gels can be used concurrently. Antiadhesion compositions may also be used to lubricate tissues and / or medical instruments, and / or deliver drugs to the surgical site and release them locally.

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.

A process for reducing the protein content and preserving the capsular polysaccharide content in a complex cellular Streptococcus pneumoniae lysate broth prior to purification is described. Utilizing pH reduction after cellular lysis has resulted in a purified polysaccharide that consistently meets the protein specification, and higher recovery yields of polysaccharide during the purification process.

This invention provides a seamless capsule for synthesizing biopolymer, comprising:(a) an aqueous mixture for synthesizing biopolymer,(b) a seamless capsule layer encapsulating said aqueous mixture, formed from polysaccharide or protein, and,(c) a viscous liquid intermediate layer, present between said aqueous mixture and said seamless capsule layer, which is immiscible with water,wherein said seamless capsule has a diameter of 0.01 to 10.0 mm.This invention can also provide a method for producing the seamless capsule.

Cells grown on a microcarrier are separated from the microcarrier by enzymatically digesting the microcarrier. More specifically, chondrocytes may be grown on dextran microcarrier beadlets and then the beadlets digested using dextranase to separate the chondrocytes from the carrier. Cells can also be grown on chitosan microcarriers to be used for implantation. In addition, cells can be grown on polysaccharide polymers to be used as implant devices. Various polymers serve as scaffolds for cells to be used for implantation. The polymers can be used for cell culture as well as for preparing scaffolds useful for tissue replacement such as cartilage tissue.

The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

A polysaccharide sponge characterized by having: (i) an average pore size in the range between about 10 mum to about 300 mum; (ii) an average distance between the pores being the wall thickness of the pores in the range between about 5 mum to about 270 mum; and (iii) an E-modulus of elasticity being a measure of the rigidity of the sponge in the range of about 50 kPa to about 500 kPa.

This invention relates to deployable hemostatic materials comprising chitosan fibers upon which hemostatic microporous polysaccharide microspheres and a medicament or biologically active substance are deposited. The hemostatic materials are suitable for use in controlling active bleeding from artery and vein lacerations, sealing femoral artery punctures, and controlling oozing from tissue.

The present invention provides a well treatment fluid for use in a well, the well treatment fluid comprising water; an amine-based polymer; an polysaccharide-based polymer; and an oxidizing agent that is capable of at least partially oxidizing at least the polysaccharide-based polymer. The present invention also provides a method of treating a subterranean formation penetrated by a wellbore, the method comprising the steps of: (a) forming a well treatment fluid comprising water; an amine-based polymer; a polysaccharide-based polymer; and an oxidizing agent that is capable of at least partially oxidizing at least a portion of the polysaccharide-based polymer; and (b) contacting the well treatment fluid with the subterranean formation. The present invention also provides a method of treating a subterranean formation penetrated by a wellbore, the method comprising the steps of: (a) forming a well treatment fluid comprising water; an amine-based polymer; and a polysaccharide-based polymer; (b) contacting the subterranean formation with the well treatment fluid; and (c) contacting the subterranean formation with an oxidizing agent that is capable of at least partially oxidizing at least a portion of the polysaccharide-based polymer in the well treatment fluid present therein.

The invention discloses a method of treating a patient for pleural effusion comprising percutaneously delivering an adhesive material to a pleural space of the patient. Suitable adhesive materials for performing any of the embodiments of the methods of the invention can be selected from the group consisting of hydrogels, collagen, poly(lactic acid), poly(glycolide), cyanoacrylates, glutaraldehyde, PEG, protein, and polysaccharide and derivatives thereof. The invention also discloses a pleural effusion treatment apparatus comprising an adhesive material adapted to adhere pleural membranes defining a pleural space and a pleural space access member adapted to deliver the adhesive material to the pleural space.

An implantable stimulation electrode for use with an implantable tissue stimulator, especially a pacemaker, a defibrillator, a bone stimulator or a neurostimulator includes a metal base body, optionally one or more intermediate layers disposed on the base body and a coating covering the base body and, optionally, intermediate layers in order to increase tissue compatibility. The coating should prevent tissue irritations after implantation and more particularly increase the stimulus threshold associated therewith, have very high biocompatibility and also has an anti-inflammatory effect. An increase in tissue compatibility is achieved by virtue of the fact that the coating has a polysaccharide layer made of hyaluronic acid and / or hyaluronic acid derivatives.

The present invention is directed to hemostatic wound dressings that contain a substrate for contacting a wound, wherein the substrate includes a wound-contacting surface and is fabricated at least in part from a biocompatible aldehyde-modified polysaccharide having covalently conjugated there with a hemostatic agent and to methods of providing hemostasis to a wound that include applying the wound dressing described herein to a wound.

A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof is also disclosed. Crosslinked polymers and injectable monophase hydrogels, respectively, are obtainable by each of said processes.

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin. Examples of active molecules that may be used with the multicomponent polymer of the invention include, for example, a drug, a biopolymer, for example a growth factor, a protein, a peptide, a nucleotide, a polysaccharide, a biological macromolecule or the like. The invention is further directed to the formation of functionalized crosslinked matrices, such as hydrogels, that include at least one functionalized compatibilizing polymer capable of assembly.

The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods provided can be used to facilitate the delivery of biologically active molecules.

The invention discloses a preparation method of a raw dendrobium officinale pulp beverage. The preparation method comprises the following steps of: (1), baking a fresh dendrobium officinale branch to be purple, adding water to the baked fresh dendrobium officinale branch for pulping, so as to obtain a primary serous fluid; (2), carrying out insulation treatment on the primary serous fluid, boiling and filtering the primary serous fluid, so as to obtain filter residue; (3) adding water to the filter residue for pulping, boiling and filtering the filter residue again to obtain the filter residue, repeating the sub-steps for a plurality of times, adding water to the final filter residue for the pulping, so as to obtain secondary serous fluid; (4), adding a cellulolytic enzyme into the secondary serous fluid for carrying out enzymolysis, so as to obtain an enzymolysis solution; (5) boiling and filtering the enzymolysis solution, to obtain the filter residue; (6) adding water into the filter residue for the pulping, boiling and filtering the filter residue again, to obtain the filter residue, and repeating the sub-steps for a plurality of times; (7) mixing all the filter solutions, boiling and sterilizing the mixed filter solution, so as to obtain the raw dendrobium officinale pulp beverage. The preparation method provided by the invention has the advantages that dendrobium officinale is baked, the filter residue is subjected to enzymolysis treatment, the extraction rate of functionality polyose and flavone is improved, the content of dietary fiber in the beverage is increased, and the prepared beverage color is bright and stable.

Methods are described for converting carbohydrates including, e.g., monosaccharides, disaccharides, and polysaccharides in ionic liquids to value-added chemicals including furans, useful as chemical intermediates and / or feedstocks. Fructose is converted to 5-hydroxylmethylfurfural (HMF) in the presence of metal halide and acid catalysts. Glucose is effectively converted to HMF in the presence of chromium chloride catalysts. Yields of up to about 70% are achieved with low levels of impurities such as levulinic acid.